Artisan Partners Asset Management Inc. · NYSE:APAM
Artisan Partners Asset Management — Investor Presentation (June 2022)
14 slides from Artisan Partners Asset Management's investor presentation, June 2022
Slide 1: Artisan Partners Growth Team Investor Update
Artisan Partners Growth Team June 2022 | Investor Update This is an offering of shares of an Artisan Fund and does not create a relationship between the investor and Artisan Partners. The Notes and Disclosures section of this presentation contains important information. Readers are encouraged to rev
Slide 2: The Growth Stock Valuation Premium Has Collapsed
The Growth Stock Valuation Premium Has Collapsed The Big Growers1 Relative Price-to-Sales Ratios2 x 8 7 6 5 4 2003-2019 3 Average 2 Lowest Since 1960 1 60 64 68 72 76 80 84 88 92 96 00 04 08 12 16 20 Recessions As of 1 May 2022. Source: National Bureau of Economic Research, Empirical Research Partne
Slide 3: The Growth Stock Valuation Premium Has Collapsed
The Growth Stock Valuation Premium Has Collapsed 12-Month Forward Price-to-Earnings Ratio S&P 500 Pure Growth S&P 500 Pure Value As of 1 May 2022. Source: Refinitiv – An LSEG Business. ARTISAN PARTNERS 2
Slide 4: Cloud Software—A Large Market That's Early
Cloud Software—A Large Market That’s Early Holdings Across Our Portfolios Global Opportunities Fund Global Discovery Fund Mid Cap Fund Small Cap Fund Atlassian Atlassian Atlassian Avalara HubSpot Bentley Systems Bill.com Bentley Systems Microsoft Ceridian Ceridian Blackline Veeva Systems Datadog Dat
Slide 5: Cloud Software—A Large Market That's Early
Cloud Software—A Large Market That’s Early A generational shift in how software is deployed and consumed continues to drive strong growth. There are clear strategic priorities for businesses of all sizes to digitize various aspects of their organizations. Big 3 Cloud Sales and Growth Rates1 100%
Slide 6: High Conviction Holding: Atlassian
Cloud Software—A Large Market That’s Early High Conviction Holding: Atlassian Atlas s ian C orp. P lc C las s A 30-Dec-2016 to 29-Apr-2022 US D High: 458.13 Low: 24.08 Las t: 224.83 Franchise Elements 450 A leading provider of innovative, customizable team-collaboration 400 software tools for over
Slide 7: Semiconductors: Enabling a Cleaner, Connected World
Semiconductors: Enabling a Cleaner, Connected World As the brains of modern electronics, semiconductors are critical components to several secular growth trends we believe will transform many industries over the next decade. Our holdings primarily include fabless vendors diversified across sever
Slide 8: Semiconductors: Holdings Across Our Portfolios
Semiconductors: Enabling a Cleaner, Connected World Holdings Across Our Portfolios Global Opportunities Fund Global Discovery Fund Mid Cap Fund Small Cap Fund AMD AMD Monolithic Power Monolithic Power ON Semi ON Semi ON Semi Lattice Semi Lattice Semi Entegris Allegro Microsytems Nordic Lattice Semi
Slide 9: High Conviction Holding: ON Semiconductor
Semiconductors: Enabling a Cleaner, Connected World High Conviction Holding: ON Semiconductor ON S emiconductor C orporation 15-Nov-2021 to 29-A pr-2022 US D High: 70.95 Low : 51.21 Las t: 52.11 Franchise Elements 75 A global market leader in power management and image sensors. 70 Profit Cycle Met
Slide 10: Picks and Shovels for the Biologic Drug Era
Picks and Shovels for the Biologic Drug Era BioTRAK Original 2020 Biologics Supply/Demand Assumptions Biologics have been increasingly used as alternatives to chemically Mammalian Biologic Drug Supply/Demand (in kL) manufactured, small-molecule compounds (from 21% of top 100 drug sales in 2006 to
Slide 11: Holdings Across Our Portfolios
Picks and Shovels for the Biologic Drug Era Holdings Across Our Portfolios Global Opportunities Fund Global Discovery Fund Mid Cap Fund Small Cap Fund Lonza Catalent Catalent Halozyme Danaher Azenta West Pharmaceutical Azenta Gerresheimer Azenta Repligen Evotec Avid Biosciences Sources: Artisan Part
Slide 12: High Conviction Holding: Lonza Group
Picks and Shovels for the Biologic Drug Era High Conviction Holding: Lonza Group Lonz a G roup A G 30-Dec-2016 to 29-A pr-2022 CHF High: 784.60 Low : 159.23 Las t: 578.40 Franchise Elements 800 A leading biopharmaceutical contract manufacturer with global reach, 750 scale advantages and scientific
Slide 13: Notes and Disclosures
Notes and Disclosures This section of this presentation contains information important to a complete understanding of the material presented. Please review it carefully. Carefully consider the Fund’s investment objective, risks and charges and expenses. This and other important information is contai
Slide 14: Notes and Disclosures
Notes and Disclosures This summary represents the views of the portfolio managers as of 3 June 2022. Securities named in the Commentary; but not listed here are not held in the Portfolios as of the date of this report. The holdings mentioned comprise the following percentages of each fund’s net asse
Artisan Partners Asset Management — Investor Presentation (June 2022) on 6ix